Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial

BACKGROUND: Germ cell tumors represent highly curable disease even in metastatic stage. However, poor-risk patients with an unfavorable serum tumor marker (STM) decline after the first cycle of chemotherapy represent a subgroup with dismal prognosis, with approximately 50% cure rate using bleomycin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mego, Michal, Rejlekova, Katarina, Svetlovska, Daniela, Miskovska, Vera, Gillis, Ad J.M., De Angelis, Valentina, Kalavska, Katarina, Obertova, Jana, Palacka, Patrik, Reckova, Maria, Sycova-Mila, Zuzana, Pindak, Daniel, Chovanec, Michal, Looijenga, Leendert H.J., Mardiak, Jozef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Testis Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551461/
https://www.ncbi.nlm.nih.gov/pubmed/34738090
http://dx.doi.org/10.1016/j.euros.2021.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551461/
https://www.ncbi.nlm.nih.gov/pubmed/34738090
http://dx.doi.org/10.1016/j.euros.2021.09.002

Ejemplares similares